Neue Erkenntnisse zum endogenen Cushing-Syndrom

Zusammenfassung

Das endogene Cushing-Syndrom ist eine seltene und potentiell verheerend verlaufende Erkrankung, welche durch inadäquat hohe Kortisol-Konzentrationen hervorgerufen wird. Selbst nach biochemischer Heilung leiden betroffene Patienten an einer ausgeprägten Mobidität und erhöhten Mortalität. Der vorliegende Artikel umschreibt einige kürzlich veröffentlichte Erkenntnisse auf diesem Gebiet, welche ein besseres Verständnis der Erkrankung ermöglichen.

Abstract

Endogenous Cushing’s syndrome is a rare but devastating endocrine disease which is caused by inappropriately elevated cortisol levels. Even after biochemical cure patients often suffer from severe morbidity and increased mortality. This manuscript addresses some currently published findings on this field, allowing for a better understanding of the disease.

Schlüsselwörter

ACTH - Cortisol - Genetik - Glukokortikoide - Hypercortisolismus - Medikation - Mortalität - subklinisch - Therapie

Keywords

ACTH - cortisol - genetics - glucocorticoids - hypercortisolism - medication - mortality - subclinical - treatment

• Literatur

• 1 Assié G, Libé R, Espiard S et al. ARMC5 mutations in macronodular adrenal hyperplasia with Cushing’s syndrome. N Engl J Med 2013; 369: 2105-2114
• 2 Beuschlein F, Fassnacht M, Assié G et al. Constitutive activation of PKA catalytic subunit in adrenal Cushing’s syndrome. N Engl J Med 2014; 370: 1019-1028
• 3 Reincke M, Sbiera S, Hayakawa A et al. Mutations in the deubiquitinase gene USP8 cause Cushing’s disease. Nat Genet 2015; 47: 31-38
• 4 Petersenn S, Beckers A, Ferone D et al. Therapy of endocrine disease: outcomes in patients with Cushing’s disease undergoing transsphenoidal surgery: a systematic review assessing criteria used to define remission and recurrence. Eur J Endocrinol 2015; 172: R227-R239
• 5 Ritzel K, Beuschlein F, Mickisch A et al. Clinical review: outcome of bilateral adrenalectomy in Cushing’s syndrome: a systematic review. J Clin Endocrinol Metab 2013; 98: 3939-3948
• 6 Colao A, Petersenn S, Newell-Price J et al. Pasireotide B2305 Study Group. A 12-month phase 3 study of pasireotide in Cushing’s disease. N Engl J Med 2012; 366: 914-924
• 7 Castinetti F, Guignat L, Giraud P et al. Ketoconazole in Cushing’s disease: is it worth a try?. J Clin Endocrinol Metab 2014; 99: 1623-1630
• 8 Valassi E, Crespo I, Gich I et al. A reappraisal of the medical therapy with steroidogenesis inhibitors in Cushing’s syndrome. Clin Endocrinol (Oxf) 2012; 77: 735-742
• 9 Deutschbein T, Petersenn S. Screening for Cushing’s syndrome: new immunoassays require adequate normative data. Horm Metab Res 2013; 45: 118-123
• 10 Bertagna X, Pivonello R, Fleseriu M et al. LCI699, a potent 11β-hydroxylase inhibitor, normalizes urinary cortisol in patients with Cushing’s disease: results from a multicenter, proof-of-concept study. J Clin Endocrinol Metab 2014; 99: 1375-1383
• 11 Lambert JK, Goldberg L, Fayngold S et al. Predictors of mortality and long-term outcomes in treated Cushing’s Disease: a study of 346 patients. J Clin Endocrinol Metab 2013; 98: 1022-1030
• 12 Dekkers OM, Horváth-Puhó E, Jorgensen JO et al. Multisystem morbidity and mortality in Cushing’s syndrome: a cohort study. J Clin Endocrinol Metab 2013; 98: 2277-2284
• 13 van der Pas R, Leebeek FW, Hofland LJ et al. Hypercoagulability in Cushing’s syndrome: prevalence, pathogenesis and treatment. Clin Endocrinol (Oxf) 2013; 78: 481-488
• 14 Debono M, Bradburn M, Bull M et al. Cortisol as a marker for increased mortality in patients with incidental adrenocortical adenomas. J Clin Endocrinol Metab 2014; 99: 4462-4470
• 15 Di Dalmazi G, Berr CM, Fassnacht M et al. Adrenal function after adrenalectomy for subclinical hypercortisolism and Cushing’s syndrome: a systematic review of the literature. J Clin Endocrinol Metab 2014; 99: 2637-2645